Germline mutations of the RET proto-oncogene, which codes for a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). MEN 2 mutations have been shown to result in RET oncogenic activation. The RET gene encodes several isoforms whose biological properties, when altered by MEN 2 mutations, have not been thoroughly addressed yet. In this study, we have introduced a MEN 2A mutation (Cys634?Arg) and the unique MEN 2B mutation (Met918?Thr) in two RET isoforms of 1114 and 1072 amino acids which dier in the carboxy-terminus part. Herein, we report that each RET isoform activated by MEN 2A or MEN 2B mutation was transforming in ®broblasts and induced neuronal dierentiation of pheochromocytoma PC12 cells. However, among the dierent RET-MEN 2 mutants, the long RET isoform activated by the MEN 2B mutation stimulated the most prominent neurite outgrowth in PC12 cells, while the short RET isoform counterpart elicited a very weak dierentiation eect in PC12 cells. We further demonstrate that the morphological changes of PC12 cells caused by constitutively activated RET oncoproteins involved the engagement of a Ras-dependent pathway. These ®ndings provide evidence that the biological properties of RET-MEN 2 mutants depend on the interplay between the RET isoforms and the nature of the activating MEN 2 mutation.
Introduction
Neurocristopathy, a concept coined by Bolande (1974) , designates a constellation of diseases arising from aberrant neural crest development. Amongst inherited neurocristopathies, multiple endocrine neoplasia type 2 (MEN 2) and Hirschsprung disease (HSCR) have now been recognized to be caused by germline mutations of the RET proto-oncogene. The RET gene codes for a transmembrane tyrosine kinase protein (Takahashi et al., 1988) which acts as a receptor for the glial-cell derived neurotrophic factor (Durbec et al., 1996; Jing et al., 1996; Trupp et al., 1996; Treanor et al., 1996) . The extracellular region of the RET protein displays a cadherin-like domain (Schneider, 1992 ) and a cysteinerich motif. Two RET isoforms which dier by nine and 51 amino acids (here referred to as RET9 and RET51) in the C-terminal domain (Tahira et al., 1990) and three additional putative RET isoforms diverging in the extracellular region are encoded by spliced mRNA variants. During development, the RET gene is highly expressed in parts of the central nervous system, in neural crest cells forming the enteric, sympathetic and dorsal root ganglia, as well as in the embryonic kidney (Pachnis et al., 1993; Tsuzuki et al., 1995) . In addition, RET is expressed in human tumours of neural crest origin, namely medullary thyroid carcinoma (MTC) and pheochromocytoma (Santoro et al., 1990) .
MEN 2 comprises three neural crest disorders inherited in an autosomal dominant fashion, MEN type 2A (MEN 2A), type 2B (MEN 2B) and familial MTC (FMTC) (reviewed in DeLellis, 1995) . MEN 2A is characterized by the association of MTC, a tumour of thyroid C-cells, pheochromocytoma and parathyroid hyperplasia. In addition to the thyroid cancer, MEN 2B associates pheochromocytoma, mucosal neuromas, ganglioneuromatosis of the digestive tract and skeletal abnormalities. In FMTC, MTC occurs alone in aected kindreds. It has become evident that allelic germline mutations of the RET gene account for the three MEN 2 syndromes (for review see DeLellis, 1995) . Missense mutations at one of ®ve cysteines clustered in the extra-cytoplasmic domain of RET (Cys 609, 611, 618, 620 and 634) have been identi®ed in the majority of the MEN 2A families and in approximately two-thirds of FMTC (Donis-Keller et al., 1993; Mulligan et al., 1993 Mulligan et al., , 1994 Schuenecker et al., 1994) . In some FMTC families without cystein mutations, two distinct missense mutations at residues located in the RET tyrosine kinase domain have been shown to cosegregate with the disease Bolino et al., 1995) . Finally, a single point mutation at codon 918, leading to the replacement of a methionine by a threonine within the catalytic core of the kinase domain, has been detected in more than 95% of MEN 2B cases (Carlson et al., 1994; Eng et al., 1994; Hofstra et al., 1994; Rossel et al., 1995) .
The observation that RET mutations are heterozygous in MEN 2-associated tumours, with both the wild type and mutated alleles being expressed, led to the suggestion that MEN 2 mutations might convert RET to a dominantly acting oncogene. Recently, evidence has been provided that MEN 2A mutations located at one of ®ve cysteines in the extracellular region, cause constitutive signaling of the tyrosine kinase through the formation of disul®de-linked RET homodimers Santoro et al., 1995) . The RET mutation in MEN 2B appears to change the catalytic speci®city of the RET tyrosine kinase (Santoro et al., 1995; Songyang et al., 1995) . Both the RET-MEN 2A and the RET-MEN 2B proteins are transforming when expressed in ®broblasts Santoro et al., 1995; Borrello et al., 1995) .
Germline mutations of the RET gene cause a dominantly inherited form of HSCR, a disease characterized by the absence of ganglion cells in the hindgut. The nature of the mutations and functional studies strongly indicate that HSCR mutations result in the loss of RET function (reviewed in Pasini, 1996) . Furthermore, mice homozygous for a disruptive mutation in the RET gene lack enteric ganglia throughout the intestinal tract (Schuchardt et al., 1994) .
Several members of the receptor tyrosine kinase gene family, such as Trk, FGFR and FLT/KDR encode structurally diverse proteins with distinct biological activities (Lamballe et al., 1993; Mueneke and Schell, 1995; Fournier et al., 1995) . Similarly, it is conceivable that each RET isoform might ful®ll dierent biological functions. The identi®cation in a family with HSCR of a RET missense mutation in exon 20 which codes for the carboxy terminus speci®c to the long isoform (AttieÂ et al., 1995) strengthens the conception that RET isoforms could have intrinsic speci®city during development and contribute unequally to the pathogenesis of HSCR and MEN 2. In order to explore this hypothesis we focused our study on two RET isoforms, RET9 and RET51, which appear to be coexpressed in MTC and pheochromocytomas (Santoro et al., 1990; Myers et al., 1995) . We now report that RET9 and RET51 isoforms activated by MEN 2A and MEN 2B mutations display distinct biochemical and biological properties.
Results

Engineering of retroviruses expressing MEN 2 mutant forms of RET
Mutation at codon 634 is the causal mutation in 85% of MEN 2A families and 30% of FMTC Schuenecker et al., 1994) . We introduced into the cDNAs coding for 1114 and 1072 amino acids isoforms of human RET, a mutation at codon 634 (TGC?CGC) which results in the substitution of a cysteine for an arginine, and the unique MEN 2B mutation at codon 918 (ATG?ACG) which leads to the replacement of a methionine for a threonine. The long and short RET isoforms which dier by 51 and nine amino acids in the C-terminus, will be referenced here as RET51 and RET9 respectively (Figure 1 ). Wild type and mutant cDNAs were cloned into the retroviral vector pBabe Puro (Morgenstern and Land, 1990b) and placed under the control of the Moloney mouse leukemia virus (Mo-MuLV) long terminal repeat (LTR). The resulting retroviral constructs were transfected into BOSC 23 cells to produce ecotropic replicative-de®cient recombinant retroviruses (Pear et al., 1993) .
Eects of MEN 2 mutations on RET9 and RET51 kinase activity
It has been shown that MEN 2A and MEN 2B mutations lead to a constitutive activation of the RET tyrosine kinase Santoro et al., 1995; Borrello et al., 1995) . However, a comparison of the biochemical features of the short and long RET isoform carrying the MEN 2 mutations has not been addressed yet. NIH3T3 cells were infected with recombinant retroviruses at equivalent multiplicity of infection and mass populations of resistant cells were obtained by selecting with puromycin. Immunoprecipitations with a rabbit polyclonal serum speci®c for an intracellular motif common to both RET isoforms were performed on cell lysates. We observed that RET9 with MEN 2 mutations were expressed at higher levels than RET9 and RET51 wild type proteins or RET51 MEN 2 mutants (data not shown). This result might be explained by a longer half-life of the RET9-MEN 2 proteins (Santoro et al., 1995; Borrello et al., 1995) and by a toxic eect of overexpressed RET51-MEN 2 isoforms. Therefore, the amount of RET protein was adjusted for each immunoprecipitate. Western blotting of these samples with the anti-RET serum revealed two forms of RET, one of 150 kDa and the other of 170 kDa (Figure 2a ). Biochemical analyses of RET have suggested that the 170 kDa RET protein is a mature glycosylated membrane-bound form of RET, while the 150 kDa RET protein represents an immature form, partially glycosylated, and present in the endoplasmic reticulum (Taniguchi et al., 1991; Asai et al., 1995) . The same immunoblot was reprobed with an antiphosphotyrosine monoclonal antibody (4G10). Figure 2b shows that both RET wild type isoforms are weakly phosphorylated, although RET51 was found consistently more phosphorylated than RET9. The level of tyrosine phosphorylation of the 170 kDa RET form was markedly increased in the RET-MEN 2 mutants, with no signi®cant dierences among the RET MEN 2 mutants. To ascertain that MEN 2 mutations result in a constitutive RET tyrosine kinase activity, we performed an immune complex kinase assay using the Myelin Basic Protein (MBP) as a substrate (Figure 3a) . Quanti®cation of MBP phosphorylation by RET showed that the kinase function of RET51 and RET9 with MEN 2 mutations was signi®cantly more active than wild type counterparts (in a descending order: RET51 -634R 4 RET9 -918T 4 RET51 -918T; RET9-634R44RET9 wt; RET51 wt).
To further substantiate that MEN 2 mutations constitutively activate the RET tyrosine kinase activity towards bona ®de substrates, we next examined the phosphorylation status of Shc. Shc is a protein involved in the early events of the activation of the Ras signaling pathway and is known to be tyrosine phosphorylated by activated forms of RET (van Weering, 1995) . Equal amounts of proteins were immunoprecipitated with an agarose-conjugated antiphosphotyrosine monoclonal antibody. The resulting immunocomplex was Western blotted and probed with antibodies recognizing Shc. Our data showed that MEN 2 forms of RET eectively stimulated the phosphorylation of Shc (Figure 3b ). Taken together, these results demonstrated that MEN 2A and MEN 2B mutations lead to a ligand-independent activation of the two RET tyrosine kinase isoforms.
Transforming capacity of MEN 2A and MEN 2B mutant RET isoforms
We next studied the transforming ability of the RET MEN 2 isoforms. For that purpose we assessed the anchorage-independent growth in soft agar of Rat1 ®broblasts stably expressing wild type and mutant RET alleles. Three weeks after plating, macroscopic colonies were present in each Petri dish corresponding to the Rat1 cells expressing the MEN 2 mutant forms of RET9 and RET51 (Figure 4 ), whereas few colonies were present in the control plates (Rat1 cells infected with retroviruses expressing b-galactosidase, wild type RET9 and RET51).
We next quantitated the transforming ability of the MEN 2 mutant forms of RET. As shown in Table 1 , the number of colonies formed in semisolid medium was comparable for Rat1-expressing RET9 ± 634, RET51 ± 634 and RET51 ± 918, whereas the number of colonies obtained with RET9 ± 918 was signi®cantly lower than that induced by the other set of RET mutants (Table 1) .
MEN 2A and MEN 2B RET alleles induce neuronal dierentiation of PC12 cells
The rat pheochromocytoma PC12 cell line has been instrumental to explore the signal transduction path- (Borrello et al., 1995) . However, the role of each RET isoform and the quantitation of the RET-induced neurite elaboration have not been evaluated. During the course of this study we found that infection of PC12 cells with ecotropic retrovirus was rather inecient compared with transfection with cationic liposomes. Therefore, the cDNAs encoding the dierent forms of RET were subcloned in the eukaryotic expression vector pJ7O (Morgenstern and Land, 1990a) and placed under the control of the simian cytomegalovirus (CMV) IE94 promoter/enhancer. To con®rm that neurite-bearing cells expressed the mutant forms of RET, we further engineered a vector in which the encephalomyocarditis virus internal ribosome entry site (IRES) allowed the coexpression of RET alleles and bgeo, a chimeric protein with both b-galactosidase and neomycin phosphotransferase activities (Friedrich and Soriano, 1991) . The IRES sequence allows internal ribosome entry into mRNA and translation initiation (reviewed in Mountfrod and Smith, 1995) . Therefore, the RET-IRES-bgeo mRNA is a bicistronic transcript and detection of the bgeo enzymatic activity in a cell ensured that RET was produced from the same fusion transcript. We ®rst con®rmed that utilisation of these vectors in Rat1 cells reproduced the results obtained with retrovirus expressing RET-MEN 2 (data not shown). PC12 cells transfected with vector expressing b-galactosidase (data not shown) or vectors expressing wild types RET did not exhibit a substantial change in morphology (Figure 5a and d) . In contrast, expression of the RET mutants in PC12 cells promoted elaboration of neurites that showed growth-cone like extensions. Staining with a chromogenic substrate of the b-galactosidase con®rmed that induction of the neuronal phenotype was restricted to transfected PC12 cells coexpressing mutant RET and bgeo ( Figure 5 ). This switch of phenotype from chroman cells to sympathetic neuron-like cells was observed with both RET9 and RET51 carrying speci®c mutations at Cys634 (Figure 5b and e). An intricate neuritic network was induced with RET51 mutated at Met 918 while the short isoform mutated at the same residue elicited a poor eect (Figure 5c and f). Timecourse experiments were carried out with the mutant RET-IRES-bgeo constructs. Within 48 h after transfection, cells expressing MEN 2 mutant forms of RET extended short neurite-like processes. The morphological dierentiation peaked at 90 h, with transfected cells sending out long branching neurites followed by progressive retraction of the processes. By 140 h most of the neurites had degenerated, and RET-expressing cells were polygonal and enlarged (data not shown).
Quantitation of the RET-induced neurite outgrowth
To quantitate the RET-mediated eect in PC12 cells, neurite-bearing cells were scored 90 h after transfection with pJ7O/RET expression vectors. To exclude that variations of transfection eciency could bias our results we exploited the pJ7O/RET-IRES-bgeo vectors. Using these vectors, we could take into account the ratio of the number of cells transfected expressing bgalactosidase and elaborating neurites to the number of cells expressing b-galactosidase. A cell was considered (Table 2) . Furthermore, RET51 ± 918 was six to seven times more potent in stimulating neurite outgrowth than the short isoform counterpart displaying the same mutation ( Table 2) .
Requirement of Ras for the neurite outgrowth induced by RET MEN 2A and MEN 2B alleles
Activation of Ras is a critical step in the signal transduction pathways acting downstream of receptor tyrosine kinases (van der Geer et al., 1994; Marshall, 1995) . To investigate if the signal transduced from mutant RET was conveyed through Ras, we chose to use a PC12 cell line stably expressing a dominant inhibitory Ras mutant, Ras Asn 17`N 17 cells' (Rodriguez-Viciana et al., 1994) . Nerve growth factor (NGF)-induced neurite outgrowth is blocked in these cells (Rodriguez-Viciana et al., 1994) . We ®rst con®rmed that N17 cells and PC12 cells expressed TrkA and p75, respectively the high and low anity NGF receptors, at comparable levels (Figure 6b and c).
Then we showed that treatment of N17 cells with NGF induced a rapid autophosphorylation of TrkA but not of the extracellular-regulated kinase 1 (ERK1) and ERK2 (Figure 6a and d) . This ®nding is consistent with the expected function of the Ras dominantinterfering mutant which disrupts the Ras downstream signaling and prevents the activation of MEK and ERK kinases. RET-IRES-bgeo constructs were transfected into Asn 17 Ras-expressing PC12 cells. Cells were stained with X-gal either 4 days or 10 days after transfection. Figure 7 shows (7) NGF. Equal amounts of PC12 and N17 cell lysates were subjected to immunoblotting with anti-phosphotyrosine antibody as described by Miyasaka and coworkers (1991) established that the short and long RET isoforms activated by MEN 2 mutations are oncogenic in ®broblasts and induce neuronal dierentiation when expressed in pheochromocytoma PC12 cells. Moreover, we showed that the magnitude of the biological eects elicited by the RET-MEN 2 proteins signi®cantly diered between each other. In particular, the long and short RET isoforms harboring the MEN 2B mutation, displayed contrasting eects, with RET51-MEN 2B and RET9-MEN 2B being respectively a potent and a weak inducer of neuronal dierentiation of PC12 cells. Fibroblast transformation and dierentiation of PC12 cells are believed to be caused by the constitutive signaling of MEN 2 forms of RET Borrello, 1995; Santoro, 1995) . Accordingly, we showed that RET-MEN 2 isoforms displayed a constitutive autokinase activity and phosphorylated the transduction protein Shc. Shc is tethered to autophosphorylated tyrosine kinase receptors and becomes phosphorylated. Tyrosine-phosphorylated Shc binds Grb2 and is involved in the early events of the Ras signaling cascade (reviewed in Pawson, 1995) . The signal transduced from receptor tyrosine kinases act partly through the activation of Ras to the GTPbound form, which promotes the stepwise stimulation of the Raf, MEK and ERK cascade (reviewed in van der Geer et al., 1994; Marshall et al., 1995) . Overexpression of oncogenic Ras (locked in the GTPbound state) protein causes transformation of fibroblasts and terminal dierentiation of various neural crest-derived cells, including PC12 cells (reviewed in Marshall, 1995) . Our experiments lend support to the notion that Ras is a critical component of the signal mediated by RET-MEN 2 since expression of a dominant interfering N17 Ras mutant abolished the RET-induced neurite outgrowth of PC12 cells. Recently, van Weering et al. (1995) showed that epidermal growth factor (EGF) treatment of cells expressing a chimaeric protein encompassing the extracellular domain of the EGF receptor (EGFR) and the kinase domain of the short RET isoform (EGFR/RET) led to the phosphorylation of Shc and subsequently resulted in the activation of Ras and the ensuing MAP kinase cascade. Taken together, these results buttress the notion that stimulation of Ras plays an important role in the mitogenic signaling mediated by activated RET.
The long RET isoform possesses two additional tyrosine residues (Y1090 and Y1096) in its Cterminus, among which Tyr-1096 has been identi®ed as an autophosphorylation site. Interestingly, Tyr-1096 is a binding site for Grb2 (Liu et al., 1996) , a bridging molecule which links Ras-activator Sos (Son of sevenless) to receptor tyrosine kinases (van der Geer et al., 1994; Pawson, 1995) . It was thus conceivable that the long RET isoform with MEN 2 mutations might activate the Ras signaling cascade with a greater eciency than the short RET isoform counterpart. However, we did not observe signi®cant dierences in the transforming ability of RET51 and RET9 with MEN 2A mutations. Furthermore, it appears that Tyr-1096 is not autophosphorylated by the RET-MEN 2B protein (Liu et al., 1996) , making it unlikely that the binding of Grb2 on Tyr-1096 of RET51 and a subsequent increased stimulation of the Ras pathway might explain the potent biological eects of this RET-MEN 2 mutant. The underlying molecular mechanism of this phenomenon remains to be determined. While this work was being completed, Iwashita and coworkers (Iwashita et al., 1996) reported that the long RET isoform with the MEN 2B mutation is approximately twofold more transforming than the same RET isoform with a MEN 2A mutation (Cys634 to Arg). We did not observe such a dierence in the transforming ability of RET51 MEN 2B and RET51 MEN 2A. It is possible that this discrepancy might re¯ect a dierence of sensitivity of the two tests used to assess ®broblast transformation, namely focus formation assay (Iwashita et al., 1996) and growth in semisolid medium described in this article.
Pheochromocytoma is a tumour found in approximately 50% of MEN 2A and MEN 2B cases DeLellis, 1995) . It is thus intriguing that MEN 2 forms of RET mostly induce growth arrest and dierentiation of PC12 cells. This apparent contradiction might be resolved if we assume that the number of active RET receptor molecules on the surface of PC12 cells is the key event which dictates the resulting biological consequences. High versus low numbers of active RET receptors on the surface of PC12 cells could trigger either a sustained ERK activation and produce dierentiation, or a transient ERK stimulation and result in increased proliferation (Cowley et al., 1994; Marshall, 1995) . In line with this hypothesis, we observed that stable transfected PC12 cell lines weakly expressed the mutant RET proteins (data not shown). The dramatic importance of the number of RET proteins at the cell surface is further emphasized by the haploinsucient nature of most of the RET germline mutations in HSCR which causes a reduced overall level of expression of the functional RET (reviewed in Pasini, 1996) . However, we cannot exclude that RET transmits a signal evoking a neuronal pathway in neuro-endocrine cells. This model might account for the neuronal properties of malignant thyroid C-cells in MEN 2-associated tumours (Russo et al., in press) .
It is likely that the net output signal transduced via RET-MEN 2 molecules will depend on the stochiometry of the dierent RET isoforms expressed in the tissues aected in MEN 2. Our results emphasize the need to analyze the time-course of expression of RET isoforms during development, as well as to quantify their respective expression in MEN 2-associated tumours. A third RET isoform which diers in the C-terminus by 43 amino acids has recently been described (Myers et al., 1995) . Work is underway to assess the biological properties of this protein while activated by MEN 2 mutations.
Alterations of the RET gene are causative of two human hereditary diseases, since mutation causes either loss or a gain of function and subsequent development of a congenital malformation or a cancer syndrome. Future experiments on the signaling pathways activated by mutant RET isoforms should yield insights into the molecular bases of MEN 2.
Materials and methods
Construction of vectors
The cDNA pN6 (Tahira et al., 1990) which codes for the 1114 amino acids RET isoform was used to construct the expression vectors used in this study. Because pN6 is a 5.5 kb full length cDNA including a long 3' non translated region, we subcloned the coding region of pN6. To assemble the pN6 open reading frame, we ampli®ed by PCR a portion of the 5' and 3' coding regions which encompassed 94 bp and 193 bp of the RET cDNA. Two new restriction sites were created by PCR, a NcoI site which modi®es the sequence 5' of the ATG start codon (the introduction of the NcoI site results in the substitution of the sequence surrounding the RET start codon into a Kozak consensus sequence [Kozak, 1989] ), and a unique MluI site 3' to the stop codon. These two PCR products, which contain both XhoI sites of the RET cDNA coding region, were subcloned into a modi®ed pBluescript SK7 (Stratagene, LaJolla, CA) whose unique XhoI site was eliminated. The resulting plasmid was digested with XhoI and the 3.0 kb cDNA Xhol ± XhoI fragment coding for RET was inserted into the vector. The pN6 cDNA coding for RET51 is mutated at codon 772, and the mutation results in the substitution of a leucine by a proline (Tahira et al., 1990) . We reintroduced the wild type sequence at codon 772 (CCG?CTG) by site-directed mutagenesis. The complete RET cDNA open reading frame cloned into pBluescript was PCR-ampli®ed with a set of 12 couples of primers and sequenced as described previously (Schuffenecker et al., 1994) . Sequence data collection and analysis were performed on a 373A DNA sequencer (Applied Biosystems, France).
The cDNA coding for the carboxy terminal portion of the short RET isoform was cloned by RT-PCR. Brie¯y, total RNA was extracted from the human neuroblastoma cell line 90-4, and cDNA was prepared with the 1st-strand cDNA Synthesis Kit (Clontech Laboratories, CA) from 1 mg of total RNA and using random hexamers as primers. The PCR product corresponding to the 100 bp of the 3' part of the RET9 open reading frame was ampli®ed with the following primers: 5'-AATAATGCCCCCCTCCCTCGAGCCCTCC-CT-3' and 5'-GATCACGCGTGACTAGAATCTAGTAAA-TGCATGGG-3'. This PCR product was digested with XhoI and MluI and ligated into pBluescript/RET51 cut with the same enzymes, thus swapping the 3' region of the RET51 cDNA for the one of RET9.
The cDNAs coding for RET51 and RET9 were subcloned either into the eucaryotic expression vector pJ7O (Morgenstern and Land, 1990a) and placed under the control of the simian cytomegalovirus promoter (CMV) or into the pBabe Puro retroviral vector (Morgenstern and Land, 1990b) . The vectors coexpressing RET and bgeo (bgalactosidase fused to neomycin phosphotransferase. [Friedrich and Soriano, 1991] ) were constructed from pJ7O-RET plasmids. We used the IRES sequence from encephalomyocarditis virus (Ghattas et al., 1991) . The IRES sequence (Ghattas et al., 1991) and the bgeo cDNA were ligated downstream of the RET cDNA. These bicistronic constructs pJ7O-RET/IRES bgeo contained the single CMV promoter which directed the expression of a bifunctional mRNA from which RET and bgeo were cotranslated.
Site-directed mutagenesis was performed with the Transformer Site-Directed Mutagenesis kit (Clontech Laboratories, CA). The mutations that changed Cys634 for Arg and Met918 for Thr were introduced by using the following oligonucleotides: 5'-TGCGACGAGCTGCGCCGCACGGT-GATCGCA-3'. 5'-CCAGTTAAATGGACGGCAATTGAA-TCC-3'. All mutations were con®rmed by DNA sequencing.
Antibodies used
Two dierent anti-RET rabbit polyclonal sera were used in this study. One antiserum has been described (Miyazaki et al., 1993) . The other antiserum was raised against a peptide corresponding to the 20 amino acids of the carboxyterminus of the short RET isoform (prepared by Biocytex, Marseille, France). Both sera recognize the long and the short RET isoforms and were used for immunoprecipitation and Western blotting at the indicated dilutions (immunoprecipitation 1:500, Western blotting 1:500 for the polyclonal obtained by Miyazaki et al. (1993) and 1:50 for the serum generated by Biocytex). Antibody directed against TrkA was a gift of LF Reichardt and was used at 1:1000; rabbit polyclonal antiserum raised against the entire human cytoplasmic domain of p75 was a gift of M Chao (serum 9993 used 1:2000). The agarose-conjugated anti-phosphotyrosine, clone 4G10 was purchased from Upstate Biotechnology Incorporated (UBI). Other antibodies used in this study were commercially available: monoclonoclonal anti-phosphotyrosine PY20 (Santa Cruz Biotechnology, Inc.) or 4G10 (UBI, NY). Rabbit polyclonal anti-Shc was purchased from UBI (NY).
Cell lines and transfection assays
NIH3T3 and Rat1 cell lines were grown in Dulbecco's modi®ed Eagle's medium (DMEM), 10% fetal calf serum (FCS) and antibiotics. The human neuroblastoma cell line 90-4 (kindly provided by S Nooner, St Jude Children's Research Hospital, Memphis, TE) was grown in RPMI 1640 with 10% FCS. PC12 cells and Ras Asn 17-expressing PC12 cells (Rodriguez-Viciana, 1994) were maintained in DMEM with 6% horse serum (Sigma) and 6% FCS (Gibco BRL). Ras Asn 17-expressing PC12 cells were routinely maintained in culture medium supplemented with 0.5 mg ml 71 of G418 (Gibco BRL). The selective antibiotic was withdrawn at least one week before lipofection. Transfections were performed with lipofectin (Gibco BRL) and Optimem reagents (Gibco BRL). PC12 cells were plated at 2610 5 or 5610 5 cells per 3.5 cm dish 2 days before transfection. For transient transfections, 20 mg of pJ7O-RET expression vector and 15 ml of lipofectin were mixed and incubated overnight in Optimem with cells. The transfection eciency was routinely between 10% and 20%.
Production of ecotropic retroviruses
pBabe Puro retroviral plasmids were transfected into the BOSC 23 packaging cell line according to the protocol described by Pear et al. (1993) . Forty-eight hours after transfection, the supernatants were harvested from 90% con¯uent BOSC 23 producer cells and ®ltered on 0.45 mm pore size ®lter. Titers of the virus supernatants were determined by infecting mouse NIH3T3 ®broblasts with various dilutions of virus in presence of 8 mg of Polybrene per ml. Forty-eight hours after infection the cells were split 1:10 into medium containing 2 mg/ml puromycin. Puromycin resistant colonies were stained and counted on day 10. Upon transfection of BOSC 23 packaging cell line, we routinely obtained titers comprised between 5610 5 and 10 6 infectious particles per milliliter.
RET protein analysis
Five hundred thousands NIH3T3 cells were seeded into a 100 mm culture dish. The day after, the cells were infected for 5 h with 10 6 infectious retroviral particles supplemented with 8 mg per ml of polybrene. Forty-eight hours after infection, cells were trypsinized, seeded at a dilution of 1:10 and fed with culture medium containing 2 mg per ml of puromycin (Sigma). Mass-selected NIH3T3 cells were rinsed with phosphate-buered saline, scraped into one milliliter of lysis buer (20 mM Tris-Cl [pH 7.8], 150 mM NaCl, 1 mM sodium orthovanadate, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl¯uoride [PMSF], 10 mg per ml aprotinin, 10 mg per ml leupeptin and 2 mM EDTA), and incubated on ice for 15 min. Lysates were pre-cleared with the rabbit preimmune serum, then subjected to immunoprecipitation with the anti-RET serum. Immune complexes were collected on protein A coupled to sepharose beads (Protein A sepharose CL4B. Pharmacia) and washed four times in lysis buer. The resulting antigen-antibody complex was suspended in Laemmli buer (20 mM Tris-HCl [pH 6.8], 2% SDS, 20% glycerol, 20 mg of bromophenol blue per ml) in the presence of 1.4 M of 2-mercaptoethanol. Proteins were boiled 3 min, then separated on an SDS ± PAGE 8% polyacrylamide gel. The gel was transferred onto polyvinylidene di¯uoride membranes (Immobilon P Millipore). Immunoblots were treated with the anti-phosphotyrosine monoclonal antibody 4G10 (UBI, NY), then incubated with anti-mouse conjugated to horse-radish peroxydase (HRP) (Amersham). The protein-antibody complex was visualized using chemiluminescence (ECL Western blotting System, Amersham). To reprobe with the anti-RET antibody, the membrane was stripped by incubating in stripping buer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.8) and incubated at 558C for 30 min. The membrane was blocked by immersing in Tris-buered saline pH 7.6 (Tris 20 mM, NaCl 137 mM) containing 0.1% of Tween-20 and 5% non fat dry milk for 1 h at room temperature. The primary anti-RET antibody was diluted in TBS-Tween milk and incubated 1 h on a rocking platform. Then, the blot was washed three times 15 min in TBS-Tween and incubated 1 h with the anti-rabbit serum conjugated to HRP (Amersham) diluted 1:5000 in TBS-Tween milk. After extensive washings in TBS-Tween, RET was detected using the ECL system.
Immunokinase assay
For in vitro kinase assays, equivalent amounts of wild type and mutant RET cellular lysates were immunoprecipitated with anti-RET serum. The immunoprecipitates, absorbed on protein A-sepharose beads, were washed twice with lysis buer, then twice with ice-cold immunokinase buer (50 mM HEPES pH 7.0, 5 mM MnCl 2 , 1 mM PMSF) and incubated for 20 min at room temperature in 30 ml of the same buer containing 50 mM MBP and 4 mCi of [g 32 P]ATP (4500 Ci/mmol ICN) diluted with unlabeled ATP to a ®nal concentration of 26 pmol/sample. The reaction was stopped by addition of concentrated Laemmli buer. Proteins were boiled 5 min, then electrophoresed on a SDS ± PAGE 15% gel.
32 P-labeled bands were revealed by autoradiography of the dried gel and quanti®ed on an Imaging Densitometer GS 670 (Biorad).
Analysis of Shc phosphorylation
NIH3T3 cells stably expressing RET alleles were starved overnight in medium containing 0.5% of fetal bovine serum. Equivalent amounts of total cellular lysates were immunoprecipitated with an agarose-conjugated antiphosphotyrosine monoclonal antibody (4G10, UBI, NY). Immune complexes were washed four times with lysis buer, then electrophoresed on a SDS ± PAGE 10% gel and subsequently transferred on PVDF membranes. Immunoblots were incubated for 2 h with polyclonal anti-Shc (UBI) according to the manufacturer instructions, then revealed with the ECL system.
Trk activation and NTR (p75) expression
PC12 and N17 cells were stimulated in absence of serum with 50 ng per ml of NGF for 5 min at room temperature. Cells were lysed in ice-cold lysis buer (20 mM Tris-Cl [pH 8.0], 137 mM NaCl, 10% Glycerol, 1% Nonidet P-40, 1 mM PMSF, 0.15 U/ml Aprotinin, 20 mM Leupeptin, 4 mM sodium orthovanadate). For immunoprecipitations, 1 mg of protein was incubated with RTA antibody or antip75 antibody for 4 h at 48C. The immune complex was then collected with Protein A-Sepharose and analysed by Western blotting as described by van Grunsven et al. (1996) .
Anchorage-independent growth of Rat1 cells
One million of Rat1 cells were seeded in a 100 mm culture plate. One day after trypsination, the cells were infected with retrovirus supernatants containing 5610 5 infectious particles per milliliter. Rat1 cells were mass-selected with puromycin as described for NIH3T3 cells. Rat1 cells were trypsinized and 10 3 cells were seeded into culture medium containing 10% FCS and 0.3% agar. Colonies were counted 3 weeks after plating.
